JAK of All Trades, Master of Some? New Research Highlights Tissue-Specific Roles of JAK Signaling
Janus kinase (JAK) inhibitors are revolutionizing the way certain inflammatory diseases such as atopic dermatitis (AD) are being treated, but a more nuanced approach may be needed in modulating JAK activity for conditions like asthma. This is the main takeaway message from a new study in the December 21, 2023, issue of Cell. For the […]
Boston Dermatologist Wins Skin Ageing & Challenges Best Scientific Award 2023 for Research on Skin Biology, Aging
Professor Vladimir A. Botchkarev, MD, PhD, a distinguished Professor of Dermatology and Co-Director at the Boston University Center for Aging Research, has received the Skin Ageing & Challenges Best Scientific Award for 2023. The award, which was presented at The Skin Ageing & Challenges 2023 Conference in Lisbon, is for his paper titled “Skin Aging in Long-Lived Naked […]
TDD Alopecia Pipeline Watch: Enrollment Complete for Equillium’s Phase 2 Study of EQ101 in AA
Equillium, Inc. has completed enrollment of the EQ101 Phase 2 study in alopecia areata, the Company reports. EQ101 is a first-in-class, selective, tri-specific inhibitor of interleukin (IL)-2, IL-9 and IL-15. The study enrolled 36 patients, of which 13, or 36%, had severe alopecia areata. The study remains ongoing, but EQ101 has been well tolerated over the […]
Evolus on the Move: Company Joins Forces With Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe
Evolus, Inc. has entered into a definitive agreement with Symatese to be the exclusive distributor in the United Kingdom (U.K.) and Europe of four unique dermal fillers in late-stage development with anticipated regulatory clearances in the second half of 2024 and commercialization under the brand name Estyme (pronounced “esteem”) fillers in 2025. This marks the second […]